Rexahn Pharmaceuticals, Inc.RNN was a big mover last session, as the company saw its shares rise more than 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $2.27 to $2.78 in the past one-month time frame.
The move came after the company announced that the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) has given positive view recommending orphan medicinal product (orphan drug) designation for RX-3117 to treat pancreatic cancer.
The company has seen one negative estimate revisions in the past few months, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few months, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.
Rexahn Pharmaceuticals, Inc. Price
Rexahn Pharmaceuticals, Inc. Price | Rexahn Pharmaceuticals, Inc. Quote
Rexahn Pharmaceuticals currently has a Zacks Rank #2 (Buy) while its Earnings ESP is positive.
Another stock worth considering in the Medical sector is Axovant Sciences Ltd. AXON which carries a Zacks Rank #1 (Strong Buy).You can see the complete list of today's Zacks #1 Rank stocks here .
Is RNN going up? Or down? Predict to see what others think: Up or Down
Wall Street's Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It's a once-in-a-generation opportunity to invest in pure genius.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Rexahn Pharmaceuticals, Inc. (RNN): Free Stock Analysis Report
Axovant Sciences Ltd. (AXON): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
